Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020
Wesley H. Self, Mark W. Tenforde, William B. Stubblefield, et al.
MMWR Morbidity and Mortality Weekly Report (2020) Vol. 69, Iss. 47, pp. 1762-1766
Open Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

Burden and characteristics of COVID-19 in the United States during 2020
Sen Pei, Teresa K. Yamana, Sasikiran Kandula, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 338-341
Open Access | Times Cited: 180
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
Andrew G. Letizia, Yongchao Ge, Sindhu Vangeti, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 7, pp. 712-720
Open Access | Times Cited: 164
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
Natalia Ortega, Marta Ribes, Marta Vidal, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 133
Reconciling estimates of global spread and infection fatality rates of COVID‐19: An overview of systematic evaluations
John P. A. Ioannidis
European Journal of Clinical Investigation (2021) Vol. 51, Iss. 5
Open Access | Times Cited: 120
An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
Cielo García‐Montero, Oscar Fraile‐Martínez, Coral Bravo, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 433-433
Open Access | Times Cited: 105
Role of miR-2392 in driving SARS-CoV-2 infection
J. Tyson McDonald, Francisco J. Enguita, Deanne Taylor, et al.
Cell Reports (2021) Vol. 37, Iss. 3, pp. 109839-109839
Open Access | Times Cited: 81
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
Vivian Glück, Sonja Grobecker, Leonid Tydykov, et al.
Infection (2021) Vol. 49, Iss. 4, pp. 739-746
Open Access | Times Cited: 57
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
Yunkai Yu, Dominic Esposito, Zhigang Kang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 43
Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years — Mississippi, May–September 2020
Charlotte V. Hobbs, Jan Drobeniuc, Theresa Kittle, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 9, pp. 312-315
Open Access | Times Cited: 50
The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery
Maddalena Peghin, Maria De Martino, Martina Fabris, et al.
Journal of Clinical Microbiology (2021) Vol. 59, Iss. 11
Open Access | Times Cited: 48
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection
Yan Zhan, Yufang Zhu, Shanshan Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 46
Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
Isabel Montesinos, Hafid Dahma, Fleur Wolff, et al.
Journal of Clinical Virology (2021) Vol. 144, pp. 104988-104988
Open Access | Times Cited: 43
Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers
Christopher D. Heaney, Nora Pisanic, Pranay R. Randad, et al.
Journal of Clinical Virology (2021) Vol. 145, pp. 104997-104997
Open Access | Times Cited: 37
Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020
Patrick S. Sullivan, Aaron J. Siegler, Kayoko Shioda, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 7, pp. 1141-1150
Open Access | Times Cited: 36
Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms
Mark A. Cappel, Jonathan A. Cappel, David A. Wetter
Mayo Clinic Proceedings (2021) Vol. 96, Iss. 4, pp. 989-1005
Open Access | Times Cited: 32
Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021
Alexia Couture, B. Casey Lyons, Megha Mehrotra, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 3
Open Access | Times Cited: 23
Impact of antenatal SARS-CoV-2 infection on development of hypertensive disorders of pregnancy in a large, diverse, cohort
Alexandra N. Mills, Bethany Dubois, Corina Lesseur, et al.
Pregnancy Hypertension (2025) Vol. 39, pp. 101205-101205
Closed Access
The BNT162b2 vaccine is associated with lower new COVID‐19 cases in nursing home residents and staff
Marsida Domi, Michael Leitson, David Gifford, et al.
Journal of the American Geriatrics Society (2021) Vol. 69, Iss. 8, pp. 2079-2089
Open Access | Times Cited: 29
kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers
José F. Varona, Rodrigo Madurga, Francisco Peñalver, et al.
European Journal of Internal Medicine (2021) Vol. 89, pp. 97-103
Open Access | Times Cited: 29
A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients
Ruben Yiqi Luo, Cassandra Yun, Indrani Chakraborty, et al.
Journal of Clinical Microbiology (2021) Vol. 59, Iss. 7
Open Access | Times Cited: 28
What do we know about the antibody responses to SARS-CoV-2?
Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia
Immunobiology (2021) Vol. 226, Iss. 2, pp. 152054-152054
Open Access | Times Cited: 27
Milk From Women Diagnosed With COVID-19 Does Not Contain SARS-CoV-2 RNA but Has Persistent Levels of SARS-CoV-2-Specific IgA Antibodies
Ryan M. Pace, Janet E. Williams, Kirsi M. Järvinen, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 27
Incidence and Prevalence of Coronavirus Disease 2019 Within a Healthcare Worker Cohort During the First Year of the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic
Sarah B. Doernberg, Marisa Holubar, Vivek Jain, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 9, pp. 1573-1584
Open Access | Times Cited: 21
SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract
Frederick Hansen, Kimberly Meade‐White, Chad S. Clancy, et al.
Cell Reports (2022) Vol. 38, Iss. 11, pp. 110515-110515
Open Access | Times Cited: 20
Policies on children and schools during the SARS-CoV-2 pandemic in Western Europe
Antoni Soriano‐Arandes, Ana Brett, Danilo Buonsenso, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top